Roger Adsett Purchases Shares in Definium Therapeutics, Inc.
Insider Roger Adsett acquired 3,555 shares of Definium Therapeutics, Inc. on June 11, 2026.
Key Points
- Roger Adsett bought 3,555 shares of Definium Therapeutics, Inc. (DFTX) on June 11, 2026, at no cost per share.
- Shares of DFTX are trading around $24.75, with a 52-week range between $6.35 and $26.25.
- Analysts like Piper Sandler and HC Wainwright & Co. have set price targets as high as $70, maintaining a 'buy' rating.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 11, 2026, Roger Adsett, an insider at Definium Therapeutics, Inc. (NasdaqGS: DFTX), acquired 3,555 shares of the company at no cost per share. This insider purchase suggests a degree of confidence in the company's future prospects.
Insider Buying and Selling at Definium Therapeutics, Inc.
Roger Adsett's recent purchase of 3,555 shares on June 11, 2026, wasn't the only insider transaction at Definium Therapeutics. Andreas Krebs also bought 19,188 shares, and Suzanne Louise Bruhn acquired 4,666 shares on the same day. All transactions were conducted without a specific plan, indicating voluntary insider confidence.
Other Institutional Activity in Definium Therapeutics
BlackRock, Inc. significantly expanded its position in Definium Therapeutics by adding 8,480,230 shares, bringing its total to 8,480,230 shares valued at about $160.3 million. Janus Henderson Group PLC also increased its holdings, ending with 3,556,041 shares worth approximately $67.2 million. Meanwhile, Driehaus Capital Management LLC reduced its stake by 625,313 shares, holding 5,911,889 shares valued at around $111.7 million.
Definium Therapeutics, Inc. Stock Down 39.6%
Shares of Definium Therapeutics, Inc. (NasdaqGS: DFTX) are trading near $24.75. The company has a market cap of approximately $2.7 billion. Although it isn't currently profitable, with a forward P/E of -15.66, it has a high beta of 2.378, indicating potential volatility. The stock's 52-week range is between $6.35 and $26.25, with moving averages of $22.33 over 50 days and $15.99 over 200 days. The company's strong liquidity is reflected in a current ratio of 4.692 and a quick ratio of 4.604.
$DFTX stock price
Daily closing prices, year to date. Not investment advice.
Analysts Set New Price Targets
On May 8, 2026, Piper Sandler maintained a 'buy' rating on Definium Therapeutics with a price target of $48. Similarly, HC Wainwright & Co. continues to see upside potential, maintaining a 'buy' rating with a target of $70. The consensus among analysts is a 'strong buy', with an average price target of $39.87 from 15 analyst opinions.
About Definium Therapeutics
Definium Therapeutics, Inc. is a biotechnology company based in New York, focusing on developing treatments for brain health disorders. Its leading candidates include DT120, in phase 3 trials for anxiety and depressive disorders, and DT402, in phase 2 trials for autism. Led by CEO Robert Barrow, the company employs 105 people and continues to innovate in the healthcare sector.
Bottom Line
Roger Adsett's insider purchase of Definium Therapeutics shares highlights his confidence in the company's future. While the company is not yet profitable, its innovative pipeline and strong liquidity position it well in the biotech field. Investors should note that insider transactions and analyst ratings often provide insight into market sentiment, but they are one piece of the broader investment puzzle.
Get Definium Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $DFTX, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.